Clinical Trial Update: Dopamine D3 Receptor Occupancy in Bipolar Depression [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating dopamine D3 receptor occupancy in bipolar depression has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Depression

Snippet

Sponsor: New York State Psychiatric Institute | Conditions: Bipolar Depression | Phase 4 | Status: WITHDRAWN